Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Trillium Therapeutics (TRIL) has announced changes in the company’s board of directors, effective immediately.
  • Paul Walker has been appointed to the board of directors.
  • Dr Ali Behbahani has been made a Board Observer.
  • Company Chief Scientific Officer, Dr Robert Uger, has resigned from the board of directors.
  • Trillium’s share price is down 1.6 per cent, with shares trading at $4.92 apiece.

Immuno-oncology company Trillium Therapeutics (TRIL) has announced changes made to the board of directors, effective as of February 6th 2020.

The changes include the resignation of Trillium’s Chief Scientific Officer, and 2 new additions, including a new Board Observer.

Paul Walker, a general partner with venture capital firm New Enterprise Associates (NEA), has been appointed to Trillium’s board of directors.

Mr Walker has a wealth of experience in the healthcare and technology industries, having worked as a general partner, life sciences investor, and portfolio manager prior to joining NEA. Mr Walker has a Bachelor of Science in Biochemistry and Cell Biology, and holds a Chartered Financial Analyst (CFA) designation.

“We are excited about Trillium’s recent progress and look forward to working with the leadership team as they expand their clinical development program,” said Mr Walker.

Dr Ali Behbahani, MD, also a general partner with NEA, has been appointed as a Board Observer. Dr Behbahani will attend Trillium board meetings, but will not be an official voting member of the board of directors.

Prior to joing NEA, Dr Behbahani has been a business development consultant, a venture associate, and a healthcare investment banking analyst. He has an MD degree and an MBA degree, earned concurrently at The University of Pennsylvania.

Trillium’s Executive Chair, Dr Robert Kirkman, commented, “We are delighted to welcome Mr Walker to the board of directors and Dr Behbahani as a Board Observer, and look forward to their guidance as we work to bring to patients our CD47 programs.”

Company Chief Scientific Officer, Dr Robert Uger, has resigned from the board of directors.

Trillium’s share price is down 1.6 per cent, with shares trading at $4.92 apiece.

More From The Market Herald
The Market Herald Video

" Algernon Pharmaceuticals (CSE:AGN) files for approval for Phase 1 DMT Human Stroke Study

Algernon (AGN) has filed a Clinical Trials of Investigational Medicinal Products and Ethics Approval application with the UK MHRA.

" Telo Genomics (TSXV:TELO) advances lead product and Implements automation to workflow

Telo Genomics (TELO) has announced a study for its lead product for smoldering multiple myeloma (SMM) patients and completed research and development projects.

" Cardiol Therapeutics (TSX:CRDL) appoints leaders in cardiovascular medicine to scientific advisory board

Cardiol Therapeutics (CRDL) has appointed Dr. Paul M. Ridker, Dr. Bruce McManus, and Dr. Joseph A. Hill to its scientific advisory board.